Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study

REFERENCES

1. 1.↵
   1. Moll JM,
   2. Wright V

   . Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55–78.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Soscia E,
   2. Sirignano C,
   3. Catalano O,
   4. Atteno M,
   5. Costa L,
   6. Caso F,
   7. et al.

   New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 2012;89:49–53.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Costa L,
   2. Caso F,
   3. D’Elia L,
   4. Atteno M,
   5. Peluso R,
   6. Del Puente A,
   7. et al.

   Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012;31:711–5.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Shang Q,
   2. Tam LS,
   3. Sanderson JE,
   4. Sun JP,
   5. Li EK,
   6. Yu CM

   . Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology 2015;51:2215–23.

   OpenUrl
5. 5.↵
   1. Haroon M,
   2. Gallagher P,
   3. Heffernan E,
   4. FitzGerald O

   . High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014;41:1357–65.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Scarpa R,
   2. Ayala F,
   3. Caporaso N,
   4. Olivieri I

   . Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210–2.

   OpenUrlFREE Full Text
7. 7.↵
   1. Taylor W,
   2. Gladman D,
   3. Helliwell P,
   4. Marchesoni A,
   5. Mease P,
   6. Mielants H;
   7. CASPAR Study Group

   . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Tillett W,
   2. Costa L,
   3. Jadon D,
   4. Wallis D,
   5. Cavill C,
   6. McHugh J,
   7. et al.

   The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39:154–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Joshi P,
   2. Dhaneshwar SS

   . An update on disease modifying antirheumatic drugs. Inflamm Allergy Drug Targets 2014;13:249–61.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Suryaprasad AG,
    2. Prindiville T

    . The biology of TNF blockade. Autoimmun Rev 2003;2:346–57.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Raychaudhuri SP

    . Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013;44:183–93.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Fiocco U,
    2. Accordi B,
    3. Martini V,
    4. Oliviero F,
    5. Facco M,
    6. Cabrelle A,
    7. et al.

    JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014;58:61–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Fiocco U,
    2. Sfriso P,
    3. Oliviero F,
    4. Lunardi F,
    5. Calabrese F,
    6. Scagliori E,
    7. et al.

    Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 2013;80:165–70.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Fiocco U,
    2. Martini V,
    3. Accordi B,
    4. Caso F,
    5. Costa L,
    6. Oliviero F,
    7. et al.

    Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol 2015;34:1571–80.

    OpenUrlPubMed
15. 15.↵
    1. Salvarani C,
    2. Pipitone N,
    3. Marchesoni A,
    4. Cantini F,
    5. Cauli A,
    6. Lubrano E,
    7. et al;
    8. Italian Society for Rheumatology

    . Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011;29:S28–41.

    OpenUrlPubMed
16. 16.↵
    1. Ash Z,
    2. Gaujoux-Viala C,
    3. Gossec L,
    4. Hensor EM,
    5. FitzGerald O,
    6. Winthrop K,
    7. et al.

    A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Armstrong AW,
    2. Coates LC,
    3. Espinoza LR,
    4. Ogdie AR,
    5. Rich P,
    6. Soriano ER

    . Infectious, oncologic, and autoimmune comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1438–41.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Shbeeb M,
    2. Uramoto KM,
    3. Gibson LE,
    4. O’Fallon WM,
    5. Gabriel SE

    . The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000;27:1247–50.

    OpenUrlPubMed
19. 19.↵
    1. Rohekar S,
    2. Tom BD,
    3. Hassa A,
    4. Schentag CT,
    5. Farewell VT,
    6. Gladman DD

    . Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008;58:82–7.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Haynes K,
    2. Beukelman T,
    3. Curtis JR,
    4. Newcomb C,
    5. Herrinton LJ,
    6. Graham DJ,
    7. et al;
    8. SABER Collaboration

    . Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48–58.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Frentz G,
    2. Olsen JH

    . Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237–42.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Boffetta P,
    2. Gridley G,
    3. Lindelöf B

    . Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531–7.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Margolis D,
    2. Bilker W,
    3. Hennessy S,
    4. Vittorio C,
    5. Santanna J,
    6. Strom BL

    . The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778–83.

    OpenUrlPubMed
24. 24.↵
    1. Gelfand JM,
    2. Berlin J,
    3. Van Voorhees A,
    4. Margolis DJ

    . Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425–9.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Stern RS

    . Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006;142:1132–5.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Archier E,
    2. Devaux S,
    3. Castela E,
    4. Gallini A,
    5. Aubin F,
    6. Le Maître M,
    7. et al.

    Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26 Suppl 3:22–31.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Stern RS,
    2. Bagheri S,
    3. Nichols K

    . The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002;47:33–9.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Marcil I,
    2. Stern RS

    . Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042–5.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. van Lümig PP,
    2. Menting SP,
    3. van den Reek JM,
    4. Spuls PI,
    5. van Riel PL,
    6. van de Kerkhof PC,
    7. et al.

    An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol 2015;29:752–60.

    OpenUrl
30. 30.↵
    1. Nannini C,
    2. Cantini F,
    3. Niccoli L,
    4. Cassarà E,
    5. Salvarani C,
    6. Olivieri I,
    7. et al.

    Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 2009;61:801–12.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Dommasch ED,
    2. Abuabara K,
    3. Shin DB,
    4. Nguyen J,
    5. Troxel AB,
    6. Gelfand JM

    . The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035–50.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Saad AA,
    2. Ashcroft DM,
    3. Watson KD,
    4. Symmons DP,
    5. Noyce PR,
    6. Hyrich KL;
    7. BSRBR

    . Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:697–705.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Gross RL,
    2. Schwartzman-Morris JS,
    3. Krathen M,
    4. Reed G,
    5. Chang H,
    6. Saunders KC,
    7. et al.

    A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 2014;66:1472–81.

    OpenUrl
34. 34.↵
    1. Carmona L,
    2. Abasolo L,
    3. Descalzo MA,
    4. Pérez-Zafrilla B,
    5. Sellas A,
    6. de Abajo F,
    7. et al;
    8. BIOBADASER Study Group;
    9. EMECAR Study Group

    . Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011;41:71–80.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Costa L,
    2. Caso F,
    3. Atteno M,
    4. Del Puente A,
    5. Darda MA,
    6. Caso P,
    7. et al.

    Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014;33:833–9.

    OpenUrlPubMed
36. 36.
    1. Jókai H,
    2. Szakonyi J,
    3. Kontár O,
    4. Marschalkó M,
    5. Szalai K,
    6. Kárpáti S,
    7. et al.

    Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol 2013;69:523–9.

    OpenUrlCrossRefPubMed
37. 37.
    1. Di Minno MN,
    2. Iervolino S,
    3. Peluso R,
    4. Scarpa R,
    5. Di Minno G;
    6. CaRRDs study group

    . Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705–12.

    OpenUrlAbstract/FREE Full Text
38. 38.
    1. Avgerinou G,
    2. Tousoulis D,
    3. Siasos G,
    4. Oikonomou E,
    5. Maniatis K,
    6. Papageorgiou N,
    7. et al.

    Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 2011;151:382–3.

    OpenUrlCrossRefPubMed
39. 39.
    1. Atteno M,
    2. Costa L,
    3. Matarese A,
    4. Caso F,
    5. Del Puente A,
    6. Cantarini L,
    7. et al.

    The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014;33:543–7.

    OpenUrlCrossRefPubMed
40. 40.
    1. Costa L,
    2. Caso F,
    3. Atteno M,
    4. Giannitti C,
    5. Spadaro A,
    6. Ramonda R,
    7. et al.

    Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014;33:273–6.

    OpenUrlCrossRefPubMed
41. 41.
    1. Fabbroni M,
    2. Cantarini L,
    3. Caso F,
    4. Costa L,
    5. Pagano VA,
    6. Frediani B,
    7. et al.

    Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm 2014;2014:862969.

    OpenUrlPubMed
42. 42.
    1. Pompili M,
    2. Biolato M,
    3. Miele L,
    4. Grieco A

    . Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013;19:7867–73.

    OpenUrlCrossRefPubMed
43. 43.
    1. Temel T,
    2. Cansu DÜ,
    3. Korkmaz C,
    4. Kaşifoğlu T,
    5. Özakyol A

    . The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections. Int J Rheum Dis 2015;18:40–5.

    OpenUrl
44. 44.
    1. Caso F,
    2. Cantarini L,
    3. Morisco F,
    4. Del Puente A,
    5. Ramonda R,
    6. Fiocco U,
    7. et al.

    Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 2015;15:641–50.

    OpenUrlPubMed
45. 45.↵
    1. Di Minno MN,
    2. Iervolino S,
    3. Lupoli R,
    4. Russolillo A,
    5. Coppola A,
    6. Peluso R,
    7. et al.

    Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 2012;38:497–505.

    OpenUrlCrossRefPubMed